VANCOUVER, British Columbia — January 8, 2026 — Leads & Copy — NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) announced its common shares have been approved for listing on the Nasdaq Stock Market and will begin trading today under the symbol “NGEN”.
Adam Rogers, MD, Interim Chief Executive Officer of NervGen Pharma, said that the Nasdaq listing marks a defining moment in NervGen’s evolution as a leading biopharmaceutical company developing neuroreparative therapeutics.
Rogers added that with Phase 1b/2a CONNECT SCI data demonstrating improvements in function, independence, and quality of life in chronic SCI, the company is entering late-stage development. NervGen believes the listing will enhance visibility, improve liquidity, broaden its shareholder base, and drive long-term shareholder value as it advances NVG-291.
NervGen’s listing on Nasdaq follows the company’s announcement of expanded Phase 1b/2a CONNECT SCI Study data on November 24th, 2025, in which NVG-291 demonstrated durable improvement in function, independence, and quality of life in individuals with chronic SCI between 1 to 10 years post-injury. NVG-291’s ability to enable the nervous system to repair itself is supported by statistically significant improvements in upper-limb corticospinal signaling, as well as statistically significant reductions in hyperactive upper and lower-limb reticulospinal signaling.
NervGen will conduct a U.S. Food and Drug Administration (FDA) End-of-Phase 2 meeting in early 2026 to align on the development and registration pathway for NVG-291. In September 2025, the Company completed an FDA Type C meeting, during which the FDA confirmed that multiple regulatory pathways are available to support approval.
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself.
NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. Enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI.
NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.
Contacts:
Huitt Tracey, Investors
htracey@nervgen.com
604.537.2094
David Schull or Ignacio Guerrero-Ros, Ph.D., Media
Russo Partners
David.Schull@russopartnersllc.com
Ignacio.Guerrero-Ros@russopartnersllc.com
858.717.2310
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Source: NervGen Pharma
